Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 5 (2008), Issue 6 (June)

1. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation.
   Int J Radiat Oncol Biol Phys, 71(3): 873-9. [Abstract] [Full-text]
2. Totally laparoscopic Roux-en-Y duct-to-mucosa pancreaticojejunostomy after middle pancreatectomy: a consecutive nine-case series at a single institution.
   Ann Surg, 247(6): 938-44. [Abstract] [Full-text]
3. Erlotinib: the first biologic in the management of pancreatic cancer.
   Expert Opin Pharmacother, 9(9): 1595-607. [Abstract] [Full-text]
4. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?
   Curr Opin Oncol, 20(4): 454-8. [Abstract] [Full-text]
5. Pancreatic cancer stem cells.
   J Clin Oncol, 26(17): 2806-12. [Abstract] [Full-text]
6. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis.
   Cancer Cell, 13(6): 507-18. [Abstract] [Full-text]
7. Exocrine pancreatic cancer clinical factors were related to timing of blood extraction and influenced serum concentrations of lipids.
   J Clin Epidemiol, 61(7): 695-704. [Abstract] [Full-text]
8. 1,1-bis(3'-indolyl)-1-(p-substituted phenyl)methanes decrease mitochondrial membrane potential and induce apoptosis in endometrial and other cancer cell lines.
   Mol Carcinog, 47(7): 492-507. [Abstract] [Full-text]
9. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas.
   Gastroenterology, 134(7): 2080-90. [Abstract] [Full-text]
10. Solid serous adenoma of the pancreas: an uncommon but important entity.
    Eur J Surg Oncol, 34(7): 730-3. [Abstract] [Full-text]
11. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.
    Eur J Surg Oncol, 34(7): 756-64. [Abstract] [Full-text]
12. Artificial neural networks in pancreatic disease.
    Br J Surg, 95(7): 817-26. [Abstract] [Full-text]
13. CaV1.2 rather than CaV1.3 is coupled to glucose-stimulated insulin secretion in INS-1 832/13 cells.
    J Mol Endocrinol, 41(1): 1-11. [Abstract] [Full-text]
14. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.
    J Immunother, 31(6): 537-44. [Abstract] [Full-text]
15. Current diagnosis and management of unusual pancreatic tumors.
    Am J Surg, 196(1): 100-13. [Abstract] [Full-text]
16. Selective killing of Smad4-negative tumor cells via a designed repressor strategy.
    Mol Pharmacol, 74(1): 289-97. [Abstract] [Full-text]
17. Rapid and quantitative method for evaluating the personal therapeutic potential of cancer drugs.
    Anal Bioanal Chem, 391(5): 1889-97. [Abstract] [Full-text]
18. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
    Lancet, 371(9630): 2101-8. [Abstract] [Full-text]
19. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
    Hum Pathol, 39(7): 1002-10. [Abstract] [Full-text]
20. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2.
    Surgery, 144(1): 57-65. [Abstract] [Full-text]
21. Sophorolipids and their derivatives are lethal against human pancreatic cancer cells.
    J Surg Res, 148(1): 77-82. [Abstract] [Full-text]
22. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer.
    Int J Cancer, 123(4): 958-66. [Abstract] [Full-text]
23. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.
    Cancer Immunol Immunother, 57(9): 1413-20. [Abstract] [Full-text]
24. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC.
    Exp Biol Med (Maywood), 233(7): 860-73. [Abstract] [Full-text]
25. Insulinoma cell calcium-sensing receptor influences insulin secretion in a case with concurrent familial hypocalciuric hypercalcemia and malignant metastatic insulinoma.
    Eur J Endocrinol, 159(1): 81-6. [Abstract] [Full-text]
26. Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization.
    Ann Surg, 248(1): 97-103. [Abstract] [Full-text]
27. Nuclear E-cadherin immunoexpression: from biology to potential applications in diagnostic pathology.
    Adv Anat Pathol, 15(4): 234-40. [Abstract] [Full-text]
28. Molecular characterization of pancreatic neoplasms.
    Adv Anat Pathol, 15(4): 185-95. [Abstract] [Full-text]
29. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor.
    Biochem Pharmacol, 76(2): 169-78. [Abstract] [Full-text]

© 2004-2010 Pancreatic Cancer Research Today. All Rights Reserved.